Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer

PURPOSE: To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER(+)/HER2(−) breast cancer; and (ii) the pharmacodynamic effect of the agents on the biomarkers. EXPERIMENTAL DESIGN: 307 postmenopausa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dowsett, Mitch, Kilburn, Lucy, Rimawi, Mothaffar F., Osborne, C. Kent, Pogue-Geile, Katherine, Liu, Yuan, Jacobs, Samuel A., Finnigan, Melanie, Puhalla, Shannon, Dodson, Andrew, Martins, Vera, Cheang, Maggie, Perry, Sophie, Holcombe, Chris, Turner, Nick, Swift, Claire, Bliss, Judith M., Johnston, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632606/
https://www.ncbi.nlm.nih.gov/pubmed/34645649
http://dx.doi.org/10.1158/1078-0432.CCR-21-1628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632606/
https://www.ncbi.nlm.nih.gov/pubmed/34645649
http://dx.doi.org/10.1158/1078-0432.CCR-21-1628

Ejemplares similares